{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=darunavir%2Fritonavir&page=2", "query": { "intervention": "darunavir/ritonavir", "page": 2 }, "page_size": 10 }, "pagination": { "page": 2, "page_size": 10, "total_count": 74, "total_pages": 8, "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=darunavir%2Fritonavir&page=3&page_size=10", "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=darunavir%2Fritonavir&page=1&page_size=10" }, "source": "remote", "last_synced_at": "2026-10-02T19:12:12.749Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT00867152", "title": "GSK1349572 Drug Interaction With Etravirine and Either Darunavir/Ritonavir or Lopinavir/Ritonavir", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Healthy Volunteer" ], "interventions": [ { "name": "Darunavir", "type": "DRUG" }, { "name": "Etravirine", "type": "DRUG" }, { "name": "Ritonavir", "type": "DRUG" }, { "name": "Lopinavir/ritonavir", "type": "DRUG" }, { "name": "GSK1349572", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "ViiV Healthcare", "sponsor_class": "INDUSTRY", "healthy_volunteers": true, "eligibility": { "minimum_age": "18 Years", "maximum_age": "65 Years", "sex": "ALL", "summary": "18 Years to 65 Years" }, "enrollment_count": 17, "start_date": "2009-04", "completion_date": "2009-05", "has_results": false, "last_update_posted_date": "2012-02-22", "last_synced_at": "2026-10-02T19:12:12.749Z", "location_count": 1, "location_summary": "Buffalo, New York", "locations": [ { "city": "Buffalo", "state": "New York" } ], "official_url": "https://clinicaltrials.gov/study/NCT00867152" }, { "nct_id": "NCT00254046", "title": "TMC125-C206: A Phase III Study to Investigate the Efficacy, Tolerability and Safety of TMC125 as Part of an Antiretroviral Regimen, Including TMC114/Ritonavir and an Investigator-selected Optimized Background, in HIV-1 Infected Patients With Limited to no Treatment Options.", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "HIV" ], "interventions": [ { "name": "TMC125", "type": "DRUG" }, { "name": "Placebo", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Tibotec Pharmaceuticals, Ireland", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 616, "start_date": "2005-11", "completion_date": "2008-07", "has_results": false, "last_update_posted_date": "2014-06-20", "last_synced_at": "2026-10-02T19:12:12.749Z", "location_count": 32, "location_summary": "Little Rock, Arkansas • Beverly Hills, California • Los Angeles, California + 29 more", "locations": [ { "city": "Little Rock", "state": "Arkansas" }, { "city": "Beverly Hills", "state": "California" }, { "city": "Los Angeles", "state": "California" }, { "city": "San Diego", "state": "California" }, { "city": "San Francisco", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT00254046" }, { "nct_id": "NCT00925756", "title": "CCR5 Inhibitor Treatment Intensification on CD4+ T-cell Recovery", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE4" ], "conditions": [ "HIV Infections" ], "interventions": [ { "name": "Maraviroc", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "University of California, San Diego", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 32, "start_date": "2008-10-20", "completion_date": "2014-04-11", "has_results": true, "last_update_posted_date": "2020-08-19", "last_synced_at": "2026-10-02T19:12:12.749Z", "location_count": 3, "location_summary": "Los Angeles, California • San Diego, California • Torrance, California", "locations": [ { "city": "Los Angeles", "state": "California" }, { "city": "San Diego", "state": "California" }, { "city": "Torrance", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT00925756" }, { "nct_id": "NCT00677300", "title": "Raltegravir And Darunavir Antiretroviral in Antiretroviral Naive Patients", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE4" ], "conditions": [ "HIV Infections" ], "interventions": [ { "name": "Raltegravir", "type": "DRUG" }, { "name": "Darunavir", "type": "DRUG" }, { "name": "Ritonavir", "type": "DRUG" }, { "name": "Tenofovir/Emtricitabine", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Dallas VA Medical Center", "sponsor_class": "FED", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 85, "start_date": "2009-01", "completion_date": "2012-12", "has_results": false, "last_update_posted_date": "2014-09-08", "last_synced_at": "2026-10-02T19:12:12.749Z", "location_count": 2, "location_summary": "Dallas, Texas", "locations": [ { "city": "Dallas", "state": "Texas" }, { "city": "Dallas", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT00677300" }, { "nct_id": "NCT01475838", "title": "Study to Evaluate Switching From Regimens Consisting of a Ritonavir-boosted Protease Inhibitor Plus Emtricitabine/Tenofovir Fixed-Dose Combination to the Elvitegravir/Cobicistat/Emtricitabine/Tenofovir DF Single-Tablet Regimen in Virologically Suppressed, HIV-1 Infected Patients", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Acquired Immunodeficiency Syndrome", "HIV Infections" ], "interventions": [ { "name": "PI", "type": "DRUG" }, { "name": "RTV", "type": "DRUG" }, { "name": "FTC/TDF", "type": "DRUG" }, { "name": "Stribild", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Gilead Sciences", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 438, "start_date": "2011-11", "completion_date": "2014-12", "has_results": true, "last_update_posted_date": "2016-06-08", "last_synced_at": "2026-10-02T19:12:12.749Z", "location_count": 45, "location_summary": "Phoenix, Arizona • Beverly Hills, California • Hayward, California + 28 more", "locations": [ { "city": "Phoenix", "state": "Arizona" }, { "city": "Phoenix", "state": "Arizona" }, { "city": "Beverly Hills", "state": "California" }, { "city": "Beverly Hills", "state": "California" }, { "city": "Hayward", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT01475838" }, { "nct_id": "NCT00081588", "title": "An Open Label Trial of TMC114/RTV in HIV-1 Infected, Treatment-experienced Subjects.", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "HIV Infection" ], "interventions": [ { "name": "TMC114", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Tibotec Pharmaceuticals, Ireland", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 555, "start_date": "2003-11", "completion_date": "2008-12", "has_results": false, "last_update_posted_date": "2014-06-20", "last_synced_at": "2026-10-02T19:12:12.749Z", "location_count": 26, "location_summary": "Birmingham, Alabama • Beverly Hills, California • La Jolla, California + 23 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Beverly Hills", "state": "California" }, { "city": "La Jolla", "state": "California" }, { "city": "Long Beach", "state": "California" }, { "city": "Los Angeles", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT00081588" }, { "nct_id": "NCT02603107", "title": "Study to Evaluate the Safety and Efficacy of Switching From Regimens Consisting of Boosted Atazanavir or Darunavir Plus Either Emtricitabine/Tenofovir or Abacavir/Lamivudine to Bictegravir/Emtricitabine/Tenofovir Alafenamide in Virologically Suppressed HIV-1 Infected Adults", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "HIV-1 Infection" ], "interventions": [ { "name": "RTV", "type": "DRUG" }, { "name": "ATV", "type": "DRUG" }, { "name": "DRV", "type": "DRUG" }, { "name": "COBI", "type": "DRUG" }, { "name": "ATV/co", "type": "DRUG" }, { "name": "DRV/co", "type": "DRUG" }, { "name": "FTC/TDF", "type": "DRUG" }, { "name": "ABC/3TC", "type": "DRUG" }, { "name": "B/F/TAF", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Gilead Sciences", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 578, "start_date": "2015-11-20", "completion_date": "2019-12-23", "has_results": true, "last_update_posted_date": "2020-12-29", "last_synced_at": "2026-10-02T19:12:12.749Z", "location_count": 63, "location_summary": "Phoenix, Arizona • Los Angeles, California • Newport Beach, California + 49 more", "locations": [ { "city": "Phoenix", "state": "Arizona" }, { "city": "Phoenix", "state": "Arizona" }, { "city": "Los Angeles", "state": "California" }, { "city": "Los Angeles", "state": "California" }, { "city": "Los Angeles", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT02603107" }, { "nct_id": "NCT00326963", "title": "BLQ Study: A Study of a Protease Inhibitor With Fuzeon (Enfuvirtide) in Treatment-Experienced Patients With HIV-1.", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE4" ], "conditions": [ "HIV Infections" ], "interventions": [ { "name": "Background ARVs", "type": "DRUG" }, { "name": "PI", "type": "DRUG" }, { "name": "enfuvirtide [Fuzeon]", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Hoffmann-La Roche", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 142, "start_date": "2006-03", "completion_date": "2007-05", "has_results": true, "last_update_posted_date": "2016-08-16", "last_synced_at": "2026-10-02T19:12:12.749Z", "location_count": 32, "location_summary": "Phoenix, Arizona • Bakersfield, California • Beverly Hills, California + 25 more", "locations": [ { "city": "Phoenix", "state": "Arizona" }, { "city": "Bakersfield", "state": "California" }, { "city": "Beverly Hills", "state": "California" }, { "city": "Los Angeles", "state": "California" }, { "city": "Los Angeles", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT00326963" }, { "nct_id": "NCT01422369", "title": "Drug-Drug Interaction of Darunavir/Ritonavir on Pitavastatin", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE4" ], "conditions": [ "Healthy" ], "interventions": [ { "name": "Pitavastatin (NK-104)", "type": "DRUG" }, { "name": "Darunavir/Ritonavir (Prezista)", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Kowa Research Institute, Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": true, "eligibility": { "minimum_age": "18 Years", "maximum_age": "45 Years", "sex": "ALL", "summary": "18 Years to 45 Years" }, "enrollment_count": 28, "start_date": "2011-04", "completion_date": "2011-06", "has_results": true, "last_update_posted_date": "2012-07-13", "last_synced_at": "2026-10-02T19:12:12.749Z", "location_count": 1, "location_summary": "Austin, Texas", "locations": [ { "city": "Austin", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT01422369" }, { "nct_id": "NCT00525733", "title": "Standard Antiretroviral v. Multi-class Therapy in Acutely HIV-1 Infected Antiretroviral-Naïve Subjects (ADARC 2007-01)", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "NA" ], "conditions": [ "HIV Infections" ], "interventions": [ { "name": "darunavir 800 mg", "type": "DRUG" }, { "name": "FTC 200 mg/TDF 300mg", "type": "DRUG" }, { "name": "Maraviroc", "type": "DRUG" }, { "name": "Raltegravir", "type": "DRUG" }, { "name": "Ritonavir 100 mg", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Rockefeller University", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 40, "start_date": "2007-10", "completion_date": "2013-12", "has_results": true, "last_update_posted_date": "2015-03-09", "last_synced_at": "2026-10-02T19:12:12.749Z", "location_count": 2, "location_summary": "New York, New York", "locations": [ { "city": "New York", "state": "New York" }, { "city": "New York", "state": "New York" } ], "official_url": "https://clinicaltrials.gov/study/NCT00525733" } ] }